干扰素β—1α治疗慢性丙型肝炎对肝纤维化的影响  

Effect of pegylated interferon β-1α therapy on the liver fibrosis in chronic hepatitis C： a semiquantitative analysis

作　　者：饶慧瑛[1] 李静[1] 张兰芳[1] 陈焕永[2] 朱理珉[3] 魏来[1] 孙焱[1] 王豪[1] 

机构地区：[1]北京大学人民医院北京大学肝病研究所,100044 [2]哈尔滨医科大学第一附属医院 [3]天津传染病医院

出　　处：《中华医学杂志》2008年第2期96-100,共5页National Medical Journal of China

基　　金：国家“十五”科技攻关计划基金资助项目（2001BA705B06,2004BA718B10）

摘　　要：目的用干扰素β—1α（IFN-β—1α）单独或联合利巴韦林（RBV）治疗慢性丙型肝炎患者，比较治疗前后的肝组织学的变化。方法慢性丙型肝炎患者21例，其中男14例、女7例，平均年龄（50±7）岁，随机分入IFN-β-1α单独治疗组（13例）和IFN—β—1α联合RBV治疗组（8例）。共治疗24周，停药后观察24周。治疗前1年内行第1次肝组织活检，最后1次随访时（第48周）行第2次肝组织活检。对治疗前后的肝活检组织进行炎症坏死（HAI）积分、纤维化评分以及α-平滑肌肌动蛋白（α-SMA）、Ⅲ型胶原的免疫组化染色。结果（1）21例患者7例获得了持续病毒学应答（SVR）。（2）21例患者治疗前HAI（6．6±2．2）分，治疗后（4．3±2．2）分，治疗后HAI积分有明显改善（t=4．77，P〈0．01）；SVR组与非SVR组患者的HAI改善程度的差异有统计学意义（t=2．04，P〈0．05）。（3）治疗前纤维化评分为（1．7±1．2）分，治疗后（1．1±1．1）分，治疗后纤维化评分较治疗前有明显改善（t=1．92，P〈0．05）。SVR中有71．40％的患者获得了肝纤维化改善，未获得SVR的患者中有42．96％获得了肝纤维化改善。（4）21例患者治疗前后α-SMA和Ⅲ型胶原的表达有差异（t值分别为2．15、1．83，均P〈0．05）。（5）联合治疗的患者肝组织学评分更易获得改善。（6）肝组织纤维化评分与肝组织HAI积分、α-SMA评分和Ⅲ型胶原积分光密度值之间均呈正相关，相关系数分别为0．805、0．942、0．949，均P〈0．01）。结论无论患者是否获得了病毒学应答，IFN—β—1α能有效改善慢性丙型肝炎患者的肝组织情况。α-SMA评分和Ⅲ型胶原积分光密度值能较好地反映肝纤维化程度。IFN-β—1α不仅能抗丙型肝炎病毒，还能直接抑制和扭转肝纤维化的进展。Objective To access the effect of pegylated interferon （PEGIFN） β—1α on the reduction of liver fibrosis in chronic hepatitis C （HVC）. Methods Twenty-one patients with chronic HVC were divided into two groups randomly and treated with recombinant human PEGIHN-β—1α （n = 13 ） or PEGIHN- β—1α plus ribavirin （RBV） （n = 8 ） for 24 weeks, and then followed up for another 24 weeks. The clinical manifestations were observed and the clinical effects were evaluated. Biopsy was conducted before and after the treatment to analyze the histological activity index （HAI） and staging of fibrosis according the modified Knodell scoring system. Immunohistochemical analysis was used to examine the levels of or-smooth muscle actin （ α-SMA）, marker of activation of hepatic stellate cells （HSCs） , and collagen type Ⅲin the HSCs. Results Sustained viral response （SVR） was achieved in 7 patients, and end-of-treatment virologic response （ETVR） was achieved in 9 patients. The HAI after treatment was 4.3 ± 2.2, significantly lower than that before treatment （6.6 ±2.2, t = 4.77, P 〈 0.01 ）. The fibrosis score after treatment was 1.1 ＋ 1.1, significantly lower than that before treatment （ 1.7 ±1.2, t = 1.92,P 〈 0.05 ）. The ot-SMA score after treatment was 14 ±8, significantly lower than that before treatment （20 ± 11, t =2. 15, P 〈0.05）. The integrated light density of collagen type 11 after treratment was 10 ± 10, significantly lower than that before treatment （ 16±12, t = 1.83, P 〈 0.05 ）. The improvement levels of fibrosis, α-SMA score, and integrated light density of collagen type lit of the patients with SVR were all better than those of the patients without SVR; however, the differences were all not significant. The patients with combination therapy, female patients, and the patients with the HCV RNA 〈 2 × 10^6 copies/ml before treatment all showed higher levels in histology response. HAI, α-SMA level, and collagen type Ⅲvalues were all signific

关 键 词：干扰素Β 肝炎 丙型 慢性 肝硬化 胶原 

分 类 号：R686[医药卫生—骨科学]